Founder, President & Chief Executive Officer, Alzheon, Inc.
Prior to founding Alzheon, Dr. Tolar has held executive positions in life sciences companies, where he has successfully established and grown new companies, business areas and product opportunities. Dr. Tolar served as President & CEO of Knome, Inc., where he pioneered human genome interpretation systems and services for academic, pharmaceutical and clinical clients, as President & CEO at NormOxys, Inc., where he built and financed the business for novel cancer therapeutics, and as Chief Scientific Officer and Chief Business Officer at CoMentis, Inc., where he built the first clinical beta secretase inhibitor platform, and negotiated a landmark deal for the program for $1.1 billion with Astellas Pharma in 2008. Dr. Tolar held a variety of clinical development and business leadership positions at Pfizer, was instrumental in a wide range of business transactions, including acquisition of Rinat Neuroscience for $500 million in 2006, and directed programs through all stages of clinical development and FDA approvals including NDA filings.
During his academic career, Dr. Tolar served as an Assistant Professor in the Department of Neurology at Yale University School of Medicine from 1992 to 1997, where he focused on movement disorders. Dr. Tolar trained in Neurology at the Boston Medical Center, received a Ph.D. in Neuroscience for his work on the role of apolipoprotein E in Alzheimer’s disease, and published many scientific publications in the area of neuroscience and neurodegenerative disorders. Dr. Tolar received his M.D. from Charles University in Prague, where as a medical student he helped organize and lead the Velvet Revolution that toppled the communist regime in the former Czechoslovakia in November 1989.
Dr. Tolar serves on business and scientific boards including the Alzheimer’s Drug Discovery Foundation, the Alzheimer Foundation and Advance Healthcare Management Institute.
Dr. Tolar was recognized by The Medicine Maker Magazine’s Power List 2016 and 2017 as one of the Top 100 Most Influential People in the world of drug development and manufacture.